SCHEMBL1574617

SCHEMBL1574617

CCN(CC)C1CN(C(=O)Nc2ccc(C)cc2)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.54
RAB9A P51151 4/20 0.54
TAS1R3 Q7RTX0 2/20 0.51
TAS1R1 Q7RTX1 2/20 0.51
TAS1R2 Q8TE23 2/20 0.51
NAMPT P43490 1/20 0.51
GRIN2B Q13224 4/20 0.50
TSHR P16473 2/20 0.50
MAPT P10636 3/20 0.48
FAAH O00519 1/20 0.48
POLB P06746 2/20 0.48
ABL1 P00519 1/20 0.48
RIN1 Q13671 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
PAX8 Q06710 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
TP53 P04637 1/20 0.46
KMT2A Q03164 1/20 0.46
LMNA P02545 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575232 0.89 NPC1 (0.51) NPC1RAB9ATAS1R3TAS1R1TAS1R2
SCHEMBL1574949 0.87 ALOX5 (0.52) NPC1RAB9ATAS1R3TAS1R1TAS1R2
SCHEMBL1574769 0.87 KMT2A (0.52) NPC1RAB9AGRIN2BMAPTSMN1; SMN2
SCHEMBL1574517 0.87 HPGD (0.55) NPC1RAB9AGRIN2BTSHRMAPT
SCHEMBL1576548 0.86 RAB9A (0.51) NPC1RAB9ATAS1R3TAS1R1TAS1R2
SCHEMBL1574848 0.86 MAPT (0.48) NPC1RAB9AGRIN2BTSHRMAPT
SCHEMBL1574404 0.85 MAPT (0.61) NPC1RAB9ATAS1R3TAS1R1TAS1R2
SCHEMBL1574441 0.85 NPC1 (0.54) NPC1RAB9AMAPTFAAHSMN1; SMN2
SCHEMBL1575273 0.85 NPC1 (0.50) NPC1RAB9ATAS1R3TAS1R1TAS1R2
SCHEMBL1574992 0.85 NPC1 (0.57) NPC1RAB9ATSHRMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB NPC1 413/4885RAB9A 898/4885TAS1R3 4140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.